Does Tirzepatide Cause Thyroid Cancer? What the Research Actually Shows

*This article is for informational purposes only. It does not constitute medical advice. Compounded tirzepatide is not FDA-approved. Consult a licensed healthcare provider before starting any medication or making changes to your treatment plan. Individual results vary.*

---

You saw the warning in the prescribing information. Maybe a pharmacist mentioned it. The words "thyroid cancer" appeared next to "tirzepatide," and now you want a straight answer.

That is a fair response. The warning is real, and it deserves an honest explanation.

Here is the short version: tirzepatide carries an FDA black box warning about thyroid C-cell tumors, based on studies conducted in rats and mice. Tirzepatide works differently from single-agonist GLP-1 medications because it activates both GLP-1 and GIP receptors simultaneously, but that dual mechanism does not appear to change the thyroid picture in humans. Human thyroid tissue expresses both receptor types at levels far below what is found in rodents. Large clinical trials and a major real-world cohort study have not demonstrated increased medullary thyroid carcinoma rates. Two specific medical histories represent absolute contraindications, and those who have them should not use this medication.

This article explains what the warning says, where it comes from, what the dual mechanism means for thyroid biology, and exactly who should avoid tirzepatide for thyroid-related reasons.

---

The FDA Warning: What It Actually Says

The black box warning on tirzepatide states that in rodent studies, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. The prescribing information for Mounjaro (for type 2 diabetes) and Zepbound (for weight loss) states that tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

This warning applies to the entire GLP-1 receptor agonist drug class: semaglutide, liraglutide, dulaglutide, and tirzepatide all carry it. The FDA requires this labeling whenever preclinical carcinogenicity studies show a dose-dependent tumor signal, regardless of whether the same effect has been confirmed in humans.

Three elements in the warning matter. First, the animal finding is stated plainly: rodents developed thyroid C-cell tumors. Second, the FDA explicitly acknowledges that it is unknown whether this effect translates to humans. Third, the contraindications are specific and limited to patients with MTC history or MEN2.

The warning is not a conclusion that tirzepatide causes thyroid cancer in humans. It is a precautionary notice based on animal data, with firm contraindications for a defined high-risk population.

---

Tirzepatide's Dual Mechanism: Does Activating GIP Receptors Change the Risk?

Tirzepatide is categorized as a dual GIP and GLP-1 receptor agonist. It binds to receptors for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which distinguishes it from single-agonist medications like semaglutide.

A reasonable question follows: if the thyroid C-cell concern is driven by GLP-1 receptor activation, does adding GIP receptor activity create a second, additive pathway for thyroid effects?

The current evidence suggests it does not.

GIP receptors are present in some thyroid tissue, but, as with GLP-1 receptors, their expression in human C-cells appears low. The rodent carcinogenicity studies for tirzepatide were conducted using the full dual mechanism, and they produced the same pattern of C-cell findings seen with single GLP-1 receptor agonists. This suggests the thyroid signal observed in animals is driven primarily by GLP-1 receptor activation at high rodent-specific receptor densities, rather than by any additive effect of the GIP component.

The biological and mechanistic reasons why rodent data may not translate to humans are explored in the next section. Those reasons apply to tirzepatide's dual agonism as much as they apply to GLP-1-only medications.

---

Why Rodent Data May Not Translate: Receptor Density in Human Thyroid Tissue

The mechanism behind the rodent tumor findings is activation of GLP-1 receptors on thyroid C-cells. In rats and mice, thyroid C-cells express GLP-1 receptors at high density. When tirzepatide stimulates those receptors, it promotes C-cell proliferation. Sustained stimulation at high doses over long periods leads to the hyperplasia and tumor formation seen in animal studies.

Human thyroid C-cells appear to behave differently.

A study by Knudsen et al. published in *Endocrinology* in 2010 investigated this question directly. Researchers treated both rodents and non-human primates with liraglutide, a GLP-1 receptor agonist in the same drug class. Rodents developed elevated calcitonin levels and C-cell hyperplasia. Non-human primates, which have thyroid GLP-1 receptor expression patterns closer to humans, showed no such effects. Human subjects in the study had no measurable change in calcitonin levels. The authors concluded that GLP-1 receptor expression in human and primate thyroid C-cells is substantially lower than in rodent tissue. [1]

Research by Gier et al. published in the *Journal of Clinical Endocrinology and Metabolism* in 2012 examined human thyroid tissue directly. The investigators detected GLP-1 receptor expression in a minority of human C-cells, at substantially lower levels than in rodents. [2]

These findings do not eliminate the precautionary warning. They provide the biological rationale for why the animal data may not be predictive of human thyroid risk. The mechanism that drives tumor formation in rodents appears to depend on a receptor density in C-cells that human thyroid tissue does not consistently demonstrate.

---

What Clinical Trials Show

The major tirzepatide randomized controlled trials enrolled large populations and tracked adverse events systematically over years of follow-up. No cases of medullary thyroid carcinoma were reported in any of these trials.

The trials below studied FDA-approved branded tirzepatide (Mounjaro, Zepbound). Compounded tirzepatide is a separate, non-FDA-approved formulation that has not been directly evaluated in these large trials; safety and efficacy findings from the branded products are referenced here for context, not as a claim about compounded equivalents.

SURPASS-1 (2021): A randomized controlled trial enrolling adults with type 2 diabetes inadequately controlled on diet and exercise. Tirzepatide was evaluated at three dose levels against placebo for 40 weeks. No MTC cases were observed. [3]

SURMOUNT-1 (2022): The landmark weight loss trial evaluating tirzepatide 5 mg, 10 mg, and 15 mg weekly against placebo over 72 weeks in adults with obesity or overweight without diabetes. No MTC cases were identified. [4]

SURPASS-CVOT (2025): A cardiovascular outcomes trial enrolling 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Participants received tirzepatide or dulaglutide for a median follow-up period. This is the largest tirzepatide trial completed to date. No increased MTC incidence was observed. [5]

Across the tirzepatide clinical trial program, which includes additional SURPASS trials in type 2 diabetes and multiple SURMOUNT trials across weight loss indications, no randomized controlled trial has detected a case of medullary thyroid carcinoma attributable to tirzepatide.

---

Real-World Data: Where the Evidence Gets More Complex

The observational literature on GLP-1 receptor agonists and thyroid cancer presents a more nuanced picture that deserves honest engagement.

A nested case-control study published in *Diabetes Care* in 2023 by Bezin et al. examined GLP-1 receptor agonist use among patients with type 2 diabetes in a French healthcare database. The investigators found increased risk for both all thyroid cancers and medullary thyroid carcinoma specifically among patients treated with GLP-1 RAs for 1 to 3 years. The adjusted hazard ratio for MTC was 1.78 (95% CI 1.04-3.05). [6]

This finding should be stated accurately rather than minimized. At the same time, several limitations affect how much weight it can carry. The study was conducted before tirzepatide had broad market penetration, so its thyroid signal applies primarily to earlier GLP-1 medications rather than tirzepatide specifically. Observational studies cannot establish causation. Patients on GLP-1 medications may receive more frequent medical monitoring than those on alternative treatments, which can produce detection bias. The absolute number of MTC cases in the study was small, and the confidence interval for the MTC finding barely excludes 1.0.

Larger and more recent studies have not replicated this signal.

A retrospective cohort study published in *Diabetes Care* in 2025 by Morales et al. examined thyroid tumor risk among more than 460,000 patients initiating GLP-1 receptor agonists, comparing them to patients on SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas. GLP-1 receptor agonist use was not associated with increased risk of thyroid tumors in any comparison. [7]

A 2026 systematic review and meta-analysis published in the *Annals of Internal Medicine* by Ko et al. analyzed 48 randomized controlled trials involving 94,245 participants. For thyroid cancer, the analysis found an odds ratio of 1.37 (95% CI 0.82-2.31) for GLP-1 receptor agonists compared to controls, a result that is not statistically significant. The authors concluded that the evidence supports little or no increased thyroid cancer risk from these medications. [8]

The current state of the evidence: one observational study found a signal that has not been replicated in a much larger cohort study or in the most comprehensive meta-analysis of randomized trial data to date. Ongoing post-market surveillance matters, and the precautionary warning should be taken seriously, particularly for patients with known thyroid risk factors.

---

The Two Absolute Contraindications

This is not a nuanced "it depends" situation for certain patients. Two groups should never use tirzepatide or any GLP-1 receptor agonist. These are firm contraindications.

1. Personal or family history of medullary thyroid carcinoma

This includes any first-degree relative (parent, sibling, child) diagnosed with MTC, not only a personal diagnosis. MTC can have a hereditary basis. Family history of MTC is an established genetic risk signal and constitutes an absolute contraindication regardless of your own current thyroid health.

2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

MEN2 is a rare inherited genetic syndrome caused by mutations in the RET proto-oncogene. It dramatically increases the lifetime risk of medullary thyroid carcinoma. Both MEN2A and MEN2B are absolute contraindications to GLP-1 receptor agonist use.

These contraindications apply across all GLP-1 receptor agonists and dual agonists: tirzepatide, semaglutide, liraglutide, dulaglutide, and their compounded equivalents.

If you have a known RET gene mutation, a family history of MEN2, or unexplained elevated calcitonin levels, your prescribing provider needs this information before any GLP-1 or dual GIP/GLP-1 medication is considered.

---

What About Other Thyroid Conditions?

The FDA black box warning is specifically about medullary thyroid carcinoma and C-cell tumors. It does not apply to papillary thyroid cancer, follicular thyroid cancer, or anaplastic thyroid cancer, which arise from different thyroid cell types entirely.

The following conditions are not contraindications to tirzepatide, though any thyroid history should be disclosed to your provider:

• Hypothyroidism (underactive thyroid), including Hashimoto's thyroiditis
• Hyperthyroidism that has been treated or controlled
• History of papillary or follicular thyroid cancer (by far the most common types; these arise from follicular cells, not C-cells, and are not addressed by the GLP-1 warning)
• Thyroid nodules that have been evaluated and found to be benign
• Benign thyroid conditions such as goiter or thyroid cysts

If you have a history of any thyroid cancer, the decision to use a GLP-1 or dual agonist medication should involve your oncologist or endocrinologist in addition to your weight loss provider. The data on non-MTC thyroid cancer and GLP-1 use is less definitive than for MTC, and personalized medical assessment matters.

---

What About Semaglutide?

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) is a GLP-1 receptor agonist in the same drug class. It carries the same black box warning about thyroid C-cell tumors. The same absolute contraindications apply: personal or family history of MTC, and MEN2.

For a detailed review of the thyroid safety data specific to semaglutide, see the companion article: [Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows](/resources/semaglutide-thyroid-cancer-risk).

---

Monitoring and When to Contact Your Provider

If you are on tirzepatide and develop any of the following symptoms, contact your provider promptly:

• A new lump or swelling in the neck
• Hoarseness or voice changes that persist
• Difficulty swallowing
• Shortness of breath without an obvious explanation

These can be symptoms of thyroid pathology. They are not expected side effects of tirzepatide, and most have causes unrelated to the medication. But they warrant evaluation. Reporting them promptly is the right call regardless of their likely cause.

Routine monitoring of calcitonin levels is not currently recommended by professional societies for all patients on GLP-1 or dual GIP/GLP-1 medications. Your provider can guide you on whether any thyroid monitoring is appropriate given your specific history.

---

How Prescriva Approaches Thyroid Safety

Every person who seeks tirzepatide through Prescriva completes a thorough medical intake that includes screening for personal and family history of thyroid cancer and MEN2. This is a clinical requirement, not a checkbox.

If a contraindication is identified, licensed healthcare providers in Prescriva's affiliated network will not prescribe a GLP-1 or dual agonist medication. The patients these contraindications apply to are not appropriate candidates, and that line does not move.

For everyone else, the prescribing decision is made by an independently licensed healthcare provider who reviews your complete medical history before writing any prescription.

---

The Bottom Line

Tirzepatide carries a black box warning about thyroid C-cell tumors because rodent studies showed dose-dependent C-cell tumor formation. Human thyroid C-cells have substantially lower GLP-1 receptor expression than rodent thyroid tissue, and the GIP receptor component of tirzepatide does not appear to change this picture. This is the likely reason the rodent effect has not been replicated in human clinical trials.

The evidence from clinical trials is reassuring: no MTC cases have been observed across the tirzepatide clinical trial program, including the SURPASS-CVOT trial involving 13,299 participants. A 2023 observational study in France found a signal for MTC risk among GLP-1 receptor agonist users, though this study had limited tirzepatide-specific data and the signal has not been replicated in a larger 2025 cohort of more than 460,000 patients or in the most comprehensive meta-analysis of randomized trial data published to date.

Two groups of patients have absolute contraindications: those with a personal or family history of MTC, and those with MEN2. For patients without these contraindications, the black box warning remains an active precaution that should be discussed with a licensed prescribing provider who can weigh your individual history against the current evidence.

If you have questions about your specific thyroid history and whether tirzepatide is appropriate for you, bring them to a licensed healthcare provider who can evaluate your full picture.

---

*This article does not constitute medical advice. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with Mounjaro or Zepbound. Individual results vary and are not guaranteed. Blue Oak Services LLC dba Prescriva is a management services organization (MSO) that does not practice medicine or make clinical decisions; medical care is delivered by independently licensed healthcare providers in Prescriva's affiliated network. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva has no affiliation with Eli Lilly and Company.*

---

Sources

1. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. *Endocrinology*. 2010;151(4):1473-1486. PMID: 20203154. [https://doi.org/10.1210/en.2009-1272](https://doi.org/10.1210/en.2009-1272)

1. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. *Journal of Clinical Endocrinology and Metabolism*. 2012;97(1):121-131. PMID: 22031513. [https://doi.org/10.1210/jc.2011-1407](https://doi.org/10.1210/jc.2011-1407)

1. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*. 2021;398(10295):143-155. PMID: 34186022. [https://doi.org/10.1016/S0140-6736(21)01324-6](https://doi.org/10.1016/S0140-6736(21)01324-6)

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*. 2022;387(3):205-216. PMID: 35658024. [https://doi.org/10.1056/NEJMoa2206038](https://doi.org/10.1056/NEJMoa2206038)

1. Nicholls SJ, Bhatt DL, Buse JB, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. *New England Journal of Medicine*. 2025. PMID: 41406444. [https://doi.org/10.1056/NEJMoa2410063](https://doi.org/10.1056/NEJMoa2410063)

1. Bezin J, Gouverneur A, Penichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. *Diabetes Care*. 2023;46(2):384-390. PMID: 36356111. [https://doi.org/10.2337/dc22-1148](https://doi.org/10.2337/dc22-1148)

1. Morales DR, Bu F, Viernes B, et al. Risk of thyroid tumors with GLP-1 receptor agonists: a retrospective cohort study. *Diabetes Care*. 2025. PMID: 40465422. [https://doi.org/10.2337/dc25-0154](https://doi.org/10.2337/dc25-0154)

1. Ko A, Chang YC, Bahar F, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. *Annals of Internal Medicine*. 2026. PMID: 41359966. [https://doi.org/10.7326/ANNALS-24-02800](https://doi.org/10.7326/ANNALS-24-02800)

1. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information. NDA 217806. 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf)